- Home
- OTLK vs ALGS Comparison
OTLK vs ALGS Comparison
Compare OTLK & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | ALGS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | 82 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 33.0M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OTLK | ALGS |
|---|---|---|
| Price | $0.78 | $4.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 23.7M | 121.7K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.91 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,146,123.00 | $2,186,000.00 |
| Revenue This Year | $1,430.98 | $32.20 |
| Revenue Next Year | $173.23 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $5.01 |
| 52 Week High | $3.39 | $13.69 |
Technical Indicators
Market Signals| Indicator | OTLK | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 74.55 | 34.64 |
| Support Level | $0.42 | N/A |
| Resistance Level | $1.18 | $6.82 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 74.57 | 7.63 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.